SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:532ceeeb-b614-450a-b496-bab82d76be46"
 

Search: onr:"swepub:oai:lup.lub.lu.se:532ceeeb-b614-450a-b496-bab82d76be46" > Application of a ri...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004824naa a2200685 4500
001oai:lup.lub.lu.se:532ceeeb-b614-450a-b496-bab82d76be46
003SwePub
008200613s2020 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/532ceeeb-b614-450a-b496-bab82d76be462 URI
0247 a https://doi.org/10.1038/s41523-020-0155-12 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Hudeček, Janu Netherlands Cancer Institute4 aut
2451 0a Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
264 c 2020-05-12
264 1b Springer Science and Business Media LLC,c 2020
520 a Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this review, we propose a new concept, namely the implementation of a risk-management framework that enables the use of sTILs as a stratification factor in clinical trials. We present the design of a biomarker risk-mitigation workflow that can be applied to any biomarker incorporation in clinical trials. We demonstrate the implementation of this concept using sTILs as an integral biomarker in a single-center phase II immunotherapy trial for metastatic TNBC (TONIC trial, NCT02499367), using this workflow to mitigate risks of suboptimal inclusion of sTILs in this specific trial. In this review, we demonstrate that a web-based scoring platform can mitigate potential risk factors when including sTILs in clinical trials, and we argue that this framework can be applied for any future biomarker-driven clinical trial setting.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Voorwerk, Leonieu Netherlands Cancer Institute4 aut
7001 a van Seijen, Maartjeu Netherlands Cancer Institute4 aut
7001 a Nederlof, Irisu Netherlands Cancer Institute4 aut
7001 a de Maaker, Michielu Netherlands Cancer Institute4 aut
7001 a van den Berg, Joseu Netherlands Cancer Institute4 aut
7001 a van de Vijver, Koen Ku Ghent University Hospital4 aut
7001 a Sikorska, Karolinau Netherlands Cancer Institute4 aut
7001 a Adams, Sylviau New York University4 aut
7001 a Demaria, Sandrau Weill Cornell Medicine4 aut
7001 a Viale, Giuseppeu University of Milan4 aut
7001 a Nielsen, Torsten Ou University of British Columbia4 aut
7001 a Badve, Sunil S4 aut
7001 a Michiels, Stefan4 aut
7001 a Symmans, William Fraseru University of Texas MD Anderson Cancer Center4 aut
7001 a Sotiriou, Christosu Université Libre de Bruxelles (ULB)4 aut
7001 a Rimm, David Lu Yale University4 aut
7001 a Hewitt, Stephen Mu National Cancer Institute, NCI4 aut
7001 a Denkert, Carstenu Philipp University of Marburg4 aut
7001 a Loibl, Sibylle4 aut
7001 a Loi, Shereneu University of Melbourne4 aut
7001 a Bartlett, John M Su Western General Hospital4 aut
7001 a Pruneri, Giancarlou University of Milan4 aut
7001 a Dillon, Deborah A4 aut
7001 a Cheang, Maggie C U4 aut
7001 a Tutt, Andrew4 aut
7001 a Hall, Jacqueline A4 aut
7001 a Kos, Zuzanau University of Ottawa4 aut
7001 a Salgado, Roberto4 aut
7001 a Kok, Marleenu Netherlands Cancer Institute4 aut
7001 a Horlings, Hugo Mu Netherlands Cancer Institute4 aut
7001 a Ehinger, Annau Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 cre0 (Swepub:lu)pat-amm
7102 a Netherlands Cancer Instituteb Ghent University Hospital4 org
7102 a International Immuno-Oncology Biomarker Working Group
7730 t npj Breast Cancerd : Springer Science and Business Media LLCg 6:1q 6:1x 2374-4677
8564 u http://dx.doi.org/10.1038/s41523-020-0155-1x freey FULLTEXT
8564 u https://www.nature.com/articles/s41523-020-0155-1.pdf
8564 8u https://lup.lub.lu.se/record/532ceeeb-b614-450a-b496-bab82d76be46
8564 8u https://doi.org/10.1038/s41523-020-0155-1

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view